ProCE Banner Activity

How I Manage Key Toxicities With Adjuvant CDK4/6 Inhibitors for Early Breast Cancer

Clinical Thought

Patients benefit the most from adjuvant CDK4/6 inhibitor therapy for HR-positive, HER2-negative early breast cancer when healthcare professionals quickly identify and manage toxicities. In this commentary, I share guidance on managing the most common and challenging toxicities: diarrhea with abemaciclib and neutropenia with ribociclib.

Released: December 22, 2023

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sarah Donahue

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC, in partnership with Breastcancer.org and Smart Patients Inc.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Smart Patients

ProCE Banner

Disclosure

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Joyce O'Shaughnessy, MD: consultant/advisor/speaker: AbbVie Inc., Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Caris, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Eli Lilly, Genentech/Roche, Gilead, Hengrui USA, Incyte Corp, Infinity Therapeutics, Jazz Pharmaceuticals, Menarini/Stemline, Merck, Natera, Novartis, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant Biopharma, Systimmune, Tango Therapeutics, Umoja Biopharma, Zentalis, Zetagen, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Seattle Genetics.

Primary Author

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Sarah Donahue, MPH, NP, AOCNP, has no relevant financial relationships to disclose.